Literature DB >> 16636975

Absence of exercise-induced leptin suppression associated with insufficient epinephrine reserve in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

F G Riepe1, N Krone, S N Krüger, F C G J Sweep, J W M Lenders, J Dötsch, H Mönig, W G Sippell, C-J Partsch.   

Abstract

OBJECTIVE: Patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency suffer from glucocorticoid and mineralocorticoid deficiency. They have insufficient epinephrine reserves and increased basal leptin levels and are often insulin resistant. In healthy subjects, an inhibitory effect of acute catecholamine elevation on the leptin plasma concentrations has been reported. However, it is not yet known how leptin levels respond to exercise in CAH patients.
METHODS: We performed a cycle ergometer test in six CAH patients to measure the response of plasma leptin, glucose and the catecholamines, epinephrine (E) and norepinephrine (N), as well as their respective metabolites, metanephrine (M) and normetanephrine (NM), to intense exercise.
RESULTS: Baseline leptin concentrations in CAH patients were not different from those of controls. Leptin levels decreased significantly with exercise in healthy controls, whereas they remained unchanged in CAH patients. In contrast to controls, CAH patients showed no rise of plasma glucose. Basal and stimulated E and M levels were significantly lower in CAH patients compared to controls. Baseline and stimulated N and NM levels were comparable, showing a significant rise after exercise. Peak systolic blood pressure and peak heart rate in both groups were comparable.
CONCLUSION: CAH patients do not manifest exercise-induced leptin suppression. The most probable reason for this is their severely impaired epinephrine stress response. In addition, epinephrine deficiency is leading to secondary changes in various catecholamine dependent metabolic pathways, e. g., energy balance. Although obvious clinical sequelae are so far unknown, the catecholamine-deficient state and the resulting hyperleptinemia might contribute to the severity of the disease in CAH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16636975     DOI: 10.1055/s-2005-865836

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  10 in total

1.  Increased Abdominal Adiposity in Adolescents and Young Adults With Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

Authors:  Mimi S Kim; Anna Ryabets-Lienhard; Anh Dao-Tran; Steven D Mittelman; Vicente Gilsanz; Sheree M Schrager; Mitchell E Geffner
Journal:  J Clin Endocrinol Metab       Date:  2015-06-10       Impact factor: 5.958

2.  Adrenomedullary function in patients with nonclassic congenital adrenal hyperplasia.

Authors:  S Verma; L Green-Golan; C VanRyzin; B Drinkard; S P Mehta; M Weise; G Eisenhofer; D P Merke
Journal:  Horm Metab Res       Date:  2010-05-05       Impact factor: 2.936

Review 3.  Clinical outcomes in the management of congenital adrenal hyperplasia.

Authors:  Henrik Falhammar; Marja Thorén
Journal:  Endocrine       Date:  2012-01-07       Impact factor: 3.633

4.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.

Authors:  Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2010-09       Impact factor: 5.958

Review 5.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

Review 6.  Cardiovascular disease risk in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Mimi S Kim; Deborah P Merke
Journal:  Semin Reprod Med       Date:  2009-06-15       Impact factor: 1.303

Review 7.  Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Felix G Riepe; Wolfgang G Sippell
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

8.  Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2008-03       Impact factor: 5.958

9.  Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 10.  Emerging medical therapies for congenital adrenal hyperplasia.

Authors:  Phyllis W Speiser
Journal:  F1000Res       Date:  2019-04-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.